1
|
van der Linden J, Zammit G, Acciaroli G, Green CR. Use of High-Glucose Alerts is Associated With Better Glycemic Control in Individuals Using Real-Time Continuous Glucose Monitoring. J Diabetes Sci Technol 2023; 17:600-601. [PMID: 36412167 PMCID: PMC10012357 DOI: 10.1177/19322968221140115] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
2
|
Di Marco T, Scammell T, Meinel M, Seboek Kinter D, Zammit G, Dauvilliers Y. Effects of daridorexant and zolpidem on night wakefulness in adults with insomnia: exploratory analysis from a randomized, double-blind, placebo-controlled phase 2 trial. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
3
|
Zammit G, Mayleben D, Fietze I, Pain S, Gimona A, Seboek Kinter D, Dauvilliers Y. Effects of daridorexant on total sleep time (TST) and sleep stage proportions in patients with insomnia disorder. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
4
|
Zammit G, Roth T, Kumar D, Perdomo C, Moline M. Impact of Lemborexant Versus Placebo and Zolpidem on REM Sleep Duration by Quarter-of-the-Night Intervals in Older Adults with Insomnia Disorder. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Zammit G, Yardley J, Pinner K, Moline M. 0479 Sleep Onset and Sleep Maintenance Responder Profiles Over 12 Months of Treatment with Lemborexant: Results from SUNRISE-2. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
In addition to analyzing treatment response by comparing change from baseline (CFB) between active treatment and placebo (PBO), it is also informative to evaluate the percent of patients with a given magnitude of response. This can help establish the expected degree of improvement for patients, thereby helping to determine treatment success.
Methods
SUNRISE-2 (NCT02952820; E2006-G000-303) was a randomized, double-blind, global phase 3 study of lemborexant (LEM) in adults (≥18y) with insomnia disorder. Subjects received PBO or LEM (5mg [LEM5]; 10mg [LEM10]) for 6mo. LEM subjects continued their original dose, while PBO subjects were rerandomized to LEM for another 6mo (not reported here). Responder profiles were constructed separately for patient-reported, sleep diary-based subjective sleep onset and sleep maintenance based on the cumulative proportion of subjects with CFBs in 10-minute increments for subjective sleep onset latency (sSOL) or subjective wake after sleep onset (sWASO), respectively. The proportion was based on number of subjects with baseline data (denominator) and data available at time of visit; study dropouts were considered nonresponders.
Results
Baseline values were similar (median sSOL [min]: PBO, 55.9; LEM5, 53.6; LEM10, 55.7; mean[SD] sWASO [min]: PBO, 132.5[80.2]; LEM5, 132.8[82.5]; LEM10, 136.8[87.4]). At 6mo, a higher percentage of subjects with CFB of ≥20min in sSOL was observed with LEM versus PBO (PBO, 30.4%; LEM5, 45.5%; LEM10, 44.9%). At 12mo, a similar percentage of responders with a ≥20min CFB in sSOL was observed for LEM (LEM5, 40.4%; LEM10, 43.3%). A higher percentage of subjects with a CFB in sWASO of ≥60min was observed for LEM versus PBO at 6mo (PBO, 24.2%; LEM5, 27.8%: LEM10, 30.2%); similar percentages were observed at 12mo with LEM (LEM5, 27.8%; LEM10, 27.7%). The majority of treatment-emergent adverse events were mild/moderate.
Conclusion
LEM treatment provided important levels of sustained efficacy over the long term. LEM was well tolerated.
Support
Eisai Inc.
Collapse
Affiliation(s)
- G Zammit
- Clinilabs Drug Development Corporation, New York, NY
| | - J Yardley
- Eisai Ltd., Hatfield, UNITED KINGDOM
| | - K Pinner
- Eisai Ltd., Hatfield, UNITED KINGDOM
| | | |
Collapse
|
6
|
Zammit G, Seboek Kinter D, Bassetti C, Leger D, Hermann V, Pain S, Roth T. 0521 Daridorexant (ACT-541468), A Dual Orexin Receptor Antagonist for the Treatment of Insomnia Disorder: Double Blind, Randomized, Phase 3 Studies for Efficacy and Safety in Adult and Elderly Patients. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.518] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Daridorexant, a potent and selective orally administered dual orexin receptor antagonist (DORA), has shown dose-dependent efficacy and is well tolerated with minimal residual next-morning effects in two phase 2 studies in adult and elderly subjects with insomnia disorder. Following the favorable phase 2 results, clinical development was pursued with two pivotal phase 3 multi-center, double-blind, randomized, placebo-controlled studies to further assess efficacy and safety in adult and elderly subjects with insomnia disorder. Long-term safety and tolerability are being further evaluated in a double-blind placebo-controlled extension study.
Methods
Each of the pivotal studies include ~900 patients (~40% ≥65y), randomized 1:1:1 to one of two daridorexant arms or placebo. The studies differ in dose only (10 or 25 mg [NCT03545191], 25 or 50 mg [NCT03575104]). Both report objective primary outcomes at 1 and 3 months based on PSG (WASO and LSP). Secondary endpoints include self-reported nighttime benefit with Total Sleep Time (sTST), and daytime benefit using the validated Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ). The patients undergo screening (7-13 d) and run-in (7-18 d) periods establishing eligibility and baseline, a 3-month double-blind treatment period, followed by a placebo run-out (7 d) to evaluate rebound insomnia and withdrawal effects and a 30-day safety follow-up. Additionally, subjects completing treatment could enroll in the 40-week double-blinded placebo-controlled extension trial [NCT03679884] to assess long-term safety.
Results
Enrollment in NCT03575104 (25/50 mg) was successfully completed and involves 76 sites across 10 countries; expected completion March 2020. Recruitment to study NCT03545191 (10/25 mg) is advanced; completion expected June 2020.
Conclusion
The comprehensive daridorexant phase 3 program includes 3 dose levels and replication of objective and subjective measurements at 1 and 3 months, while assessing self-reported nighttime benefit, and benefit during the day with a validated PRO instrument, as well as safety in insomnia disorder.
Support
Medical writing Randall Watson, (Idorsia). These studies were sponsored by Idorsia Pharmaceuticals Ltd.
Collapse
Affiliation(s)
| | | | - C Bassetti
- Inselspital Universitatsklinik für Neurologie, Bern, SWITZERLAND
| | - D Leger
- Universite Paris Descartes AP-HP, Paris, FRANCE
| | - V Hermann
- Idorsia Pharmeceuticals Ltd., Allschwil, SWITZERLAND
| | - S Pain
- Idorsia Pharmeceuticals Ltd., Allschwil, SWITZERLAND
| | - T Roth
- Division of Sleep Medicine and Research Center, Henry Ford Health System, Detroit, MI
| |
Collapse
|
7
|
Dauvilliers Y, Zammit G, Fietze I, Mayleben D, Kinter DS, Pain S, Hedner J. Daridorexant (Act-541468), a new dual orexin receptor antagonist, for the treatment of insomnia disorder: a randomized, double-blind, placebo-controlled, active-reference phase 2 study. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Kuna S, Reboussin D, Wojtanowski A, Sifferman A, Strotmeyer E, Millman R, Zammit G, Walkup M, Jakicic J, Newman A, Wadden T, Wing R, Pi-Sunyer F, Foster G. Long term effects of weight loss on obstructive sleep apnea in adults with type 2 diabetes and overweight/obesity: 10-year results of the sleep ahead study. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Moline M, Ancoli-Israel S, Zammit G, Kumar D, Huang S. Do insomnia patients in insomnia clinical trials endorse daytime sleepiness? Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Moline M, Pinner K, Cheng J, Perdomo C, Kumar D, Zammit G, Mayleben D. Effect of lemborexant compared with placebo and zolpidem extended release on sleep architecture in older adults with insomnia disorder. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.1227] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Dahl T, Roth T, Zammit G, Ahmad M, Chen L. 0005 Efficacy of SM-1 in a Transient Insomnia Model. Sleep 2018. [DOI: 10.1093/sleep/zsy061.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- T Dahl
- Sequential Medicine Ltd, Taipei, TAIWAN
| | - T Roth
- Henry Ford Hospital Sleep Disorders and Research Center, Detroit, MI
| | | | - M Ahmad
- Clinilabs Inc., New York, NY
| | - L Chen
- Sequential Medicine Ltd, Taipei, TAIWAN
| |
Collapse
|
12
|
Murphy P, Kumar D, Zammit G, Rosenberg R, Moline M. 0412 Auditory Awakening Threshold to Evaluate Ability to Awaken after Administration of Lemborexant versus Zolpidem. Sleep 2018. [DOI: 10.1093/sleep/zsy061.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - D Kumar
- Eisai Inc, Woodcliffe Lake, NJ
| | - G Zammit
- Clinilabs Sleep Disorders Institute, St. Luke’s-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY
| | | | | |
Collapse
|
13
|
Walzer M, Wu R, Ahmad M, Freeman J, Zammit G, Marek G. 0079 A Phase 1 Single-dose Polysomnography Study Of ASP8062, A GABAB Receptor Positive Allosteric Modulator. Sleep 2018. [DOI: 10.1093/sleep/zsy061.078] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- M Walzer
- Astellas Pharma Global Development, Northbrook, IL
| | - R Wu
- Astellas Pharma Global Development, Northbrook, IL
| | | | | | | | - G Marek
- Astellas Pharma Global Development, Northbrook, IL
| |
Collapse
|
14
|
Blackman A, Foster G, Zammit G, Rosenberg R, Aronne L, Wadden T, Claudius B, Jensen C, Mignot E. Liraglutide 3.0 mg reduces severity of obstructive sleep apnea and body weight in obese individuals with moderate or severe disease: scale sleep apnoea tria. Sleep Med 2015. [DOI: 10.1016/j.sleep.2015.02.058] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
15
|
Collier A, Blackman A, Foster G, Zammit G, Rosenberg R, Wadden T, Aronne L, Claudius B, Jensen T, Mignot E. S28 Liraglutide 3.0 Mg Reduces Severity Of Obstructive Sleep Apnoea And Body Weight In Obese Individuals With Moderate Or Severe Disease: Scale Sleep Apnoea Trial. Thorax 2014. [DOI: 10.1136/thoraxjnl-2014-206260.34] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
16
|
Affiliation(s)
- N J Aronoff
- St Luke's-Roosevelt Obesity Research Center, New York, NY, USA
| | | | | |
Collapse
|
17
|
Lee KA, Zammit G. Toward optimal health: the experts respond to sleep deprivation. Interview by Jodi Godfrey Meisler. J Womens Health (Larchmt) 1998; 7:1205-10. [PMID: 9929852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023] Open
|
18
|
Rosen R, Mahowald M, Chesson A, Doghramji K, Goldberg R, Moline M, Millman R, Zammit G, Mark B, Dement W. The Taskforce 2000 survey on medical education in sleep and sleep disorders. Sleep 1998; 21:235-8. [PMID: 9595601 DOI: 10.1093/sleep/21.3.235] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Previous research has shown evidence of a widening gap between scientific research and clinical teaching in sleep and sleep disorders. To address the deficiencies in current medical education in sleep, the Taskforce 2000 was established by the American Sleep Disorders Association. The present study was undertaken to assess the teaching activities, needs and interests of the membership of the two largest professional sleep societies (American Sleep Disorders Association and Sleep Research Society). Survey instruments included a brief, 5-item postcard survey, which was mailed to all members, followed by an in-depth, 34-item questionnaire, which was completed by 158 respondents from the intitial postcard survey (N = 808). Results indicated that the majority of respondents (65.2%) are currently involved in teaching sleep to medical students or postgraduate trainees, although the average amount of teaching time was only 2.1 hours for undergraduate and 4.8 hours for graduate education in sleep. Teaching of sleep laboratory procedures and clinical evaluation of sleep-disordered patients is limited at either an undergraduate or postgraduate level. The major deficiencies noted were the lack of time in the medical curriculum and the need for better resources and teaching facilities. A large majority of respondents indicated their willingness to be involved in sleep education for physicians, and rated this a high priority for the professional organization.
Collapse
Affiliation(s)
- R Rosen
- Comprehensive Sleep Disorders Center, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Zammit G, Rosenbaum A, Stokes P, Yee W. Family histories of alcoholism in depressed patients: DST and REM latency findings. Am J Psychiatry 1989; 146:1077. [PMID: 2750984 DOI: 10.1176/ajp.146.8.1077a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|